Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Health Status After Switching ACE Inhibitors or ARBs to Sacubitril-valsartan in HFrEF Patients From Rural Tanzania
NCT06704633Phase 4Recruiting
- Start
- Jun 2026
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of sacubitril + valsartan in heart failure with reduced ejection fraction (HFrEF). Started Jun 2026; status: recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT06704633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06704633.